Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

Portico IDE

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)

The PORTICO pivotal IDE trial is a prospective, multi-center, randomized, controlled clinical investigation study designed to evaluate the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and Delivery Systems (Portico) via transfemoral and alternative delivery methods in high-risk and extreme-risk patients.
Currently recruiting

Portico NG

Portico NG - Evaluation of the Navitor Transcatheter Aortic Valve in High and Extreme Risk Patients with Symptomatic Severe Aortic Stenosis

The primary objective of this clinical study is to evaluate the acute safety and effectiveness of the Navitor Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days. The results from this study will be descriptively compared to the data from the first-generation Portico Transcatheter Aortic Heart Valve and commercially available TAVI devices studied in the same patient population (e.g. high and extreme surgical risk).
Currently recruiting

POST-ETERNAL

Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (NCT05105633)

Currently recruiting

POTAT

A Pilot Study of Post Operative Iron Infusion for the Treatment of Anaemia in trauma Patients (ACTRN12624000410550)

No longer recruiting

PREDICT

PREdiction and Diagnosis using Imaging and Clinical biomarkers Trial in Traumatic Brain Injury (ACTRN12620001360909)

Currently recruiting

PrEEN

Prospective assessment of the effects of Exclusive Enteral Nutrition on inflammation, epithelial integrity and body composition in patients with Crohn’s disease (ACTRN12625000357459)

Currently recruiting

PREVAIL

Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies (NCT05142722)

Currently recruiting

PREVISION

A Prospective, Multicenter, Single Arm, Non-Randomized, Study of BD™ Sirolimus Drug Coated Balloon Catheter for Treatment of Femoropopliteal Arteries (NCT05556681)

Currently recruiting

PRIME-OOHCA

PRotecting cerebral injury and IMproving outcomEs with SGLT2 inhibitors in comatose Out-Of-Hospital Cardiac Arrest survivors – a Pilot Study (ACTRN12624001183572)

A double blinded randomised controlled pilot study comparing the outcomes of dapagliflozin vs placebo in patients with comatose cardiac arrest, with respect to hypoxic brain and ischaemia reperfusion injury
Coming soon

PRO-DVd

Patient Reported Outcomes in patients received DVd for relapsed MM (ACTRN12618000659202)

No longer recruiting

PROBE

A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (NCT04986865)

Currently recruiting

PROCORA

PROvocative CORonary testing in unexplained cardiac Arrest (ACTRN12624001248550)

Currently recruiting

Progress-AD

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease (NCT06079190)

Currently recruiting

PROSPERO

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (NCT05742802)

Currently recruiting

PRT2527-02

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)

Currently recruiting

PTeye

Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)

Currently recruiting

PTG-300-11

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PTG-300-11) (NCT05210790)

No longer recruiting

PWI in enduring PVI

Outcomes of redo atrial fibrillation ablation with posterior wall isolation in patients with enduring pulmonary vein isolation (Trial Not Registered)

To determine the effectiveness of posterior wall isolation in patients presenting for redo atrial fibrillation (AF) ablation with enduring pulmonary vein isolation (PVI).
Coming soon

QUANTUM-WILD

Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

About the QuANTUM-Wild Study: QuANTUM-Wild is a clinical trial for people who are newly diagnosed with acute myeloid leukaemia (AML) that is FLT3-ITD–negative. The purpose of the clinical trial is to evaluate an oral study drug called quizartinib—to see if it may improve this type of AML and is safe. This study drug is currently not approved for this condition, which is why it’s being evaluated. Everyone in the clinical trial will also receive the standard chemotherapy for their type of AML. This clinical trial will not delay the start of chemotherapy. Your study doctor may recommend that you receive a stem cell transplant. If so, your study doctor will be able to provide you with more information about this procedure. Although it is not part of this clinical trial, you may be able to continue participating in the clinical trial after you receive a stem cell transplant.
Currently recruiting

R3767-ONC-2011

A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672)

No longer recruiting
21 22 23 24 25